Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18904487 | ROCAGLATE DERIVATIVES AND USES THEREOF | October 2024 | February 2025 | Allow | 5 | 0 | 0 | Yes | No |
| 18800581 | NK3 MODULATORS AND USES THEREOF | August 2024 | November 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18764274 | LASOFOXIFENE TREATMENT OF BREAST CANCER | July 2024 | May 2025 | Allow | 10 | 1 | 0 | Yes | No |
| 18636905 | 3-(3-(1,3-DIOXOISOINDOLIN-2-YL) PROPYL)-5-(4-FLUOROBENZYLIDENE) THIAZOLIDINE-2,4-DIONE AS A POTENTIAL ANTITUMOR AND APOPTOTIC INDUCER | April 2024 | July 2024 | Allow | 3 | 0 | 0 | No | No |
| 18681394 | COLCHICINE SOLUTION | February 2024 | September 2024 | Allow | 7 | 1 | 0 | No | No |
| 18560806 | NOVEL PIPERIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN COMPRISING SAME | November 2023 | June 2024 | Allow | 7 | 0 | 0 | Yes | No |
| 18373404 | CYCLIC AZASTANNANE AND CYCLIC OXOSTANNANE COMPOUNDS AND METHODS FOR PREPARATION THEREOF | September 2023 | March 2024 | Allow | 6 | 1 | 0 | No | No |
| 18305332 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | April 2023 | April 2025 | Allow | 24 | 1 | 1 | Yes | No |
| 18300315 | GSPT1 COMPOUNDS AND METHODS OF USE OF THE NOVEL COMPOUNDS | April 2023 | August 2024 | Allow | 16 | 1 | 1 | No | No |
| 18166020 | BENZIMIDAZOLE DERIVATIVES COMPOSITIONS | February 2023 | October 2024 | Abandon | 21 | 1 | 0 | No | No |
| 18155431 | IRON CATALYZED HIGHLY ENANTIOSELECTIVE CIS-DIHYDROXYLATION OF QUINONES | January 2023 | December 2024 | Allow | 23 | 2 | 1 | No | No |
| 18064173 | BICYCLIC AMINES AS CDK12 INHIBITORS | December 2022 | February 2024 | Allow | 14 | 0 | 1 | No | No |
| 17988340 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | November 2022 | December 2024 | Allow | 25 | 2 | 1 | No | No |
| 17998333 | CRYSTALLINE FORMS AND FORMULATIONS OF A VCP/p97 INHIBITOR | November 2022 | June 2025 | Allow | 31 | 0 | 0 | Yes | No |
| 18046648 | CANCER TREATMENT USING FGFR INHIBITORS AND PLK1 INHIBITORS | October 2022 | December 2023 | Allow | 14 | 1 | 0 | Yes | No |
| 17916439 | CXCR5 Antagonists and Methods of Treating Diseases or Disorders Using Same | September 2022 | May 2025 | Allow | 32 | 0 | 0 | Yes | No |
| 17940576 | METHOD FOR PREPARING PHTHALONITRILE-BASED COMPOUND | September 2022 | July 2025 | Allow | 34 | 0 | 0 | Yes | No |
| 17899672 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | August 2022 | May 2025 | Allow | 33 | 0 | 0 | Yes | No |
| 17788154 | PROTEIN DEGRADATION AGENT COMPOUND PREPARATION METHOD AND APPLICATION | June 2022 | January 2025 | Allow | 31 | 0 | 0 | No | No |
| 17835245 | METHYLQUINAZOLINONE DERIVATIVES | June 2022 | August 2024 | Allow | 26 | 1 | 0 | Yes | No |
| 17772888 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | April 2022 | May 2025 | Allow | 37 | 0 | 0 | Yes | No |
| 17729691 | COMPOSITION FOR RELIEVING HANGOVER AND IMPROVING LIVER FUNCTION | April 2022 | September 2024 | Abandon | 28 | 1 | 0 | No | No |
| 17716963 | CRYSTALLINE FORMS OF N-(4-(1-(2,6-DIFLUOROBENZYL)-5-((DIMETHYLAMINO)METHYL)-3-(6-METHOXY-3-PYRIDAZINYL)-2,4-DIOXO-1,2,3,4-TETRAHYDROTHIENO[2,3-D]PYRIMIDIN-6-YL)PHENYL)-N'-METHOXYUREA | April 2022 | February 2025 | Allow | 34 | 0 | 0 | Yes | No |
| 17637439 | NOVEL LOBARIC ACID DERIVATIVE HAVING PTP-1B INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | February 2022 | February 2025 | Allow | 36 | 0 | 0 | Yes | No |
| 17628138 | COMPOSITIONS FOR TREATMENT OF SUBSTANCE USE DISORDER | January 2022 | April 2025 | Allow | 39 | 0 | 1 | Yes | No |
| 17300930 | Azaquinazoline pan-KRas inhibitors | December 2021 | February 2025 | Allow | 38 | 2 | 1 | Yes | No |
| 17534789 | PREPARING METHOD OF LINEAR CARBONATE COMPOUNDS | November 2021 | December 2024 | Allow | 37 | 2 | 0 | No | No |
| 17598883 | CANNABINOID COMPOSITIONS AND USE THEREOF | September 2021 | June 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17436647 | ANTIBODY-DRUG CONJUGATE AND USE THEREOF | September 2021 | June 2025 | Abandon | 45 | 2 | 0 | No | No |
| 17428353 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | August 2021 | May 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17427456 | TRANSIENT POTENTIAL MELASTATIN 8 (TRPM8) ANTAGONISTS AND RELATED METHODS | July 2021 | May 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17427311 | TOPICAL SANITIZING COMPOSITIONS | July 2021 | May 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17426442 | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | July 2021 | November 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17425796 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | July 2021 | November 2024 | Allow | 39 | 0 | 0 | No | No |
| 17424699 | Cholinesterase inhibitor polymorph and application thereof | July 2021 | September 2024 | Allow | 38 | 0 | 0 | Yes | No |
| 17422700 | EGFR Inhibitors, Compositions and Methods Thereof | July 2021 | February 2025 | Abandon | 43 | 1 | 0 | Yes | No |
| 17422257 | SUBSTITUTED PYRROLIDINE AMIDES III | July 2021 | March 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17421540 | MATERNAL DPA FOR BENEFIT OF MOTHER AND/OR CHILD'S MENTAL HEALTH | July 2021 | February 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17421474 | SYNERGIC PHARMACEUTICAL COMPOSITION OF ACECLOFENAC AND BETAMETHASONE FOR TREATING THE PAIN OF RHEUMATIC CONDITIONS OR POSTSURGICAL PAIN | July 2021 | December 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17420421 | ANDROGEN RECEPTOR PROTEIN DEGRADERS | July 2021 | February 2025 | Allow | 43 | 1 | 1 | No | No |
| 17420597 | METHODS AND MATERIALS FOR INCREASING TRANSCRIPTION FACTOR EB POLYPEPTIDE LEVELS | July 2021 | October 2024 | Allow | 40 | 0 | 1 | Yes | No |
| 17360699 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | June 2021 | April 2025 | Allow | 45 | 2 | 1 | Yes | No |
| 17416976 | SALICYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF | June 2021 | January 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17416997 | ORGANIC COMPOUNDS | June 2021 | September 2024 | Allow | 39 | 0 | 1 | Yes | No |
| 17416415 | KIF18A INHIBITORS | June 2021 | March 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17416411 | KIF18A INHIBITORS | June 2021 | February 2025 | Allow | 44 | 1 | 1 | No | No |
| 17413469 | HETEROCYCLIC COMPOUND | June 2021 | April 2024 | Allow | 34 | 0 | 0 | No | No |
| 17300000 | BENZIMIDAZOLE OR BENZOXAZOLE DERIVATIVES FOR PREVENTING AND TREATING CENTRAL NERVOUS SYSTEM DISEASE, DIABETES, AND COMPLICATIONS THEREOF | June 2021 | October 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17299573 | KCHIP2 MODULATOR COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | June 2021 | October 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17299325 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | June 2021 | December 2024 | Allow | 42 | 1 | 1 | Yes | No |
| 17299270 | COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | June 2021 | May 2025 | Allow | 47 | 2 | 1 | Yes | No |
| 17299267 | SMALL MOLECULE INHIBITORS OF THE BFRB:BFD INTERACTION | June 2021 | November 2024 | Allow | 41 | 1 | 1 | No | No |
| 17297407 | COMPOUNDS USEFUL TO TREAT INFLUENZA VIRUS INFECTIONS | May 2021 | February 2024 | Allow | 33 | 0 | 0 | No | No |
| 17295933 | ORAL TOPIRAMATE SUSPENSION FORMULATIONS WITH EXTENDED SHELF STABILITY AND ENHANCED BIOAVAILABILITY | May 2021 | May 2025 | Allow | 47 | 2 | 1 | Yes | No |
| 17295728 | HETEROCYCLIC COMPOUNDS AND MEDICAL USE THEREOF | May 2021 | May 2025 | Allow | 47 | 2 | 1 | Yes | No |
| 17295553 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE, MYODEGENERATIVE, AND LYSOSOMAL STORAGE DISORDERS | May 2021 | November 2024 | Allow | 42 | 1 | 1 | Yes | No |
| 17295774 | ?2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA | May 2021 | January 2025 | Abandon | 44 | 2 | 0 | Yes | No |
| 17295845 | GABOXADOL FOR REDUCING RISK OF SUICIDE AND RAPID RELIEF OF DEPRESSION | May 2021 | August 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17295600 | USE OF SHP2 INHIBITORS FOR THE TREATMENT OF INSULIN RESISTANCE | May 2021 | October 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17295522 | USE OF DANTROLENE AND DANTROLENE PRODRUGS TO TREAT RADIATION EXPOSURE | May 2021 | November 2024 | Allow | 42 | 1 | 1 | Yes | No |
| 17292846 | Pharmaceutical Composition Comprising PARP Inhibitors | May 2021 | February 2025 | Allow | 46 | 2 | 0 | Yes | No |
| 17291938 | BENZOTHIAZOLE DERIVATIVES AND 7-AZA-BENZOTHIAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | May 2021 | May 2025 | Allow | 48 | 3 | 1 | Yes | No |
| 17291582 | LIPOPHILIC ACTIVE ORAL FILM FORMULATION AND METHOD OF MAKING THE SAME | May 2021 | January 2025 | Allow | 45 | 2 | 0 | No | No |
| 17289861 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | April 2021 | October 2024 | Allow | 42 | 1 | 0 | Yes | No |
| 17289832 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | April 2021 | December 2024 | Abandon | 44 | 2 | 0 | No | No |
| 17289677 | METAL COMPLEXES FOR PROMOTING GROWTH IN A PHOTOSYNTHETIC ORGANISM | April 2021 | May 2025 | Allow | 48 | 2 | 1 | Yes | No |
| 17289646 | Targeting Redox-Active Pyridinium Cations to Mitochondria to Inhibit Proliferation of Drug-Resistant Cancer Cells | April 2021 | March 2025 | Allow | 47 | 2 | 1 | No | No |
| 17289152 | 2-AMINO-N-PHENYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | April 2021 | March 2025 | Allow | 47 | 2 | 1 | Yes | No |
| 17288780 | NOVEL INDAZOLE COMPOUND OR SALT THEREOF | April 2021 | April 2024 | Allow | 35 | 1 | 0 | Yes | No |
| 17287834 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | April 2021 | August 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17287030 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING ON DEMAND SOLID DOSAGE FORMULATIONS | April 2021 | May 2025 | Allow | 48 | 1 | 1 | Yes | No |
| 17286178 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | April 2021 | September 2024 | Allow | 41 | 1 | 1 | Yes | No |
| 17285858 | COMBINATION OF ATR KINASE INHIBITORS WITH 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE COMPOUNDS | April 2021 | July 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17285161 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING AMINOPYRIMIDINE DERIVATIVE OR ITS SALT | April 2021 | March 2025 | Allow | 47 | 3 | 0 | No | No |
| 17282748 | HYDROPHILIC AND PARTICULARLY WATER SOLUBLE DBOV-DERIVATIVES | April 2021 | February 2024 | Allow | 35 | 1 | 0 | Yes | No |
| 17205841 | Rotomeric Isomers of 4-alkyl-5-Heteroaryl-3H-1,2-Dithiole-3-Thiones | March 2021 | July 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17274933 | INDOLE-OXADIAZOLE COMPOUNDS AND THEIR THERAPEUTIC USE | March 2021 | June 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17271671 | Method for Treating Lysosomal Storage Disease | February 2021 | May 2025 | Allow | 50 | 2 | 1 | Yes | No |
| 17270372 | PYRAZOLOPYRIMIDINE DERIVATIVE AND USE THEREOF AS PI3K INHIBITOR | February 2021 | May 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17270304 | PHARMACEUTICAL COMPOSITION FOR TREATING FIBROSIS | February 2021 | June 2024 | Allow | 39 | 2 | 0 | No | No |
| 17267771 | INDAZOLE AMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | February 2021 | November 2023 | Allow | 33 | 0 | 0 | Yes | No |
| 17264284 | LOW DOSAGE INTRANASAL AMINOSTEROL DOSAGE FORMS AND METHODS OF USING THE SAME | January 2021 | November 2024 | Abandon | 46 | 1 | 1 | No | No |
| 17138605 | PROCESS FOR SEPARATING TRICYANOHEXANE | December 2020 | May 2025 | Abandon | 53 | 4 | 0 | No | No |
| 16768234 | POLYCOMB INHIBITORS AND USES THEREOF | May 2020 | May 2025 | Allow | 59 | 3 | 2 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner MCKOY, QUINCY ANDRE works in Art Unit 1626 and has examined 79 patent applications in our dataset. With an allowance rate of 69.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.
Examiner MCKOY, QUINCY ANDRE's allowance rate of 69.6% places them in the 24% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MCKOY, QUINCY ANDRE receive 1.03 office actions before reaching final disposition. This places the examiner in the 13% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by MCKOY, QUINCY ANDRE is 40 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +51.4% benefit to allowance rate for applications examined by MCKOY, QUINCY ANDRE. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 41.2% of applications are subsequently allowed. This success rate is in the 91% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 42.9% of cases where such amendments are filed. This entry rate is in the 58% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants file petitions regarding this examiner's actions, 54.5% are granted (fully or in part). This grant rate is in the 68% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.